T cell receptor (TCR) gene therapy can target the immune system to solid tumors in ways CAR-T cells can't match, but the field is still looking for a clear success. Ken Garber reports.
References
Yanagi, Y. et al. Nature 308, 145–149 (1984).
Hedrick, S.M., Cohen, D.I., Nielsen, E.A. & Davis, M.M. Nature 308, 149–153 (1984).
Dembić, Z. et al. Nature 320, 232–238 (1986).
Morgan, R.A. et al. Science 314, 126–129 (2006).
Holler, P.D. et al. Proc. Natl. Acad. Sci. USA 97, 5387–5392 (2000).
Robbins, P.F. et al. J. Clin. Oncol. 29, 917–924 (2011).
Parkhurst, M.R. et al. Mol. Ther. 19, 620–626 (2011).
Morgan, R.A. et al. J. Immunother. 36, 133–151 (2013).
Linette, G.P. et al. Blood 122, 863–871 (2013).
Schmitt, T.M. et al. Blood 122, 348–356 (2013).
Mackall, C. et al. J. Clin. Oncol. 35, suppl; abstr. 3000 (2017).
Lu, Y.C. et al. Clin. Cancer Res. 20, 3401–3410 (2014).
Tran, E. et al. Science 344, 641–645 (2014).
Deniger, D.C. et al. Mol. Ther. 24, 1078–1089 (2016).
Oda, S.K. et al. Blood 130, 2410–2419 (2017).
Corrales, L., McWhirter, S.M., Dubensky, T.W. Jr. & Gajewski, T.F. J. Clin. Invest. 126, 2404–2411 (2016).
Roybal, K.T. et al. Cell 164, 770–779 (2016).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Driving T-cell immunotherapy to solid tumors. Nat Biotechnol 36, 215–219 (2018). https://doi.org/10.1038/nbt.4090
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4090
- Springer Nature America, Inc.
This article is cited by
-
Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity
Discover Oncology (2024)
-
Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma
Cancer Immunology, Immunotherapy (2024)
-
Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues
Journal of Translational Medicine (2023)
-
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Molecular Cancer (2023)
-
Antibody-based binding domain fused to TCRγ chain facilitates T cell cytotoxicity for potent anti-tumor response
Oncogenesis (2023)